DK2249859T3 - Behandling af metastatisk prostatacancer med degarelix - Google Patents

Behandling af metastatisk prostatacancer med degarelix

Info

Publication number
DK2249859T3
DK2249859T3 DK09711390.6T DK09711390T DK2249859T3 DK 2249859 T3 DK2249859 T3 DK 2249859T3 DK 09711390 T DK09711390 T DK 09711390T DK 2249859 T3 DK2249859 T3 DK 2249859T3
Authority
DK
Denmark
Prior art keywords
degarelix
treatment
prostate cancer
metastatic prostate
metastatic
Prior art date
Application number
DK09711390.6T
Other languages
English (en)
Inventor
Bo-Eric Persson
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39718285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2249859(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Application granted granted Critical
Publication of DK2249859T3 publication Critical patent/DK2249859T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK09711390.6T 2008-02-11 2009-02-10 Behandling af metastatisk prostatacancer med degarelix DK2249859T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2774108P 2008-02-11 2008-02-11
EP08250703 2008-02-29
US14795609P 2009-01-28 2009-01-28
PCT/IB2009/000370 WO2009101533A1 (en) 2008-02-11 2009-02-10 Treatment of metastatic stage prostate cancer with degarelix

Publications (1)

Publication Number Publication Date
DK2249859T3 true DK2249859T3 (da) 2014-06-02

Family

ID=39718285

Family Applications (3)

Application Number Title Priority Date Filing Date
DK12165896T DK2505204T3 (da) 2008-02-11 2009-02-10 Fremgangsmåde til behandling af prostatakræft med GnRH-antagonisten degarelix
DK09711390.6T DK2249859T3 (da) 2008-02-11 2009-02-10 Behandling af metastatisk prostatacancer med degarelix
DK13168404.5T DK2650012T3 (da) 2008-02-11 2009-02-10 Behandling af prostatacancer i metastasestadium med degarelix.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK12165896T DK2505204T3 (da) 2008-02-11 2009-02-10 Fremgangsmåde til behandling af prostatakræft med GnRH-antagonisten degarelix

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK13168404.5T DK2650012T3 (da) 2008-02-11 2009-02-10 Behandling af prostatacancer i metastasestadium med degarelix.

Country Status (25)

Country Link
US (15) US20090203623A1 (da)
EP (7) EP2799085A1 (da)
JP (10) JP5876652B2 (da)
KR (7) KR20100123714A (da)
CN (4) CN101939020B (da)
AU (2) AU2009213748B9 (da)
BR (2) BRPI0908129A2 (da)
CA (3) CA3235099A1 (da)
CY (3) CY1115561T1 (da)
DK (3) DK2505204T3 (da)
EA (4) EA017582B1 (da)
ES (3) ES2540235T3 (da)
HK (4) HK1176552A1 (da)
HR (3) HRP20140665T1 (da)
IL (3) IL207295A (da)
JO (1) JOP20090061B1 (da)
MX (2) MX2010008817A (da)
NZ (4) NZ603958A (da)
PL (3) PL2650012T3 (da)
PT (3) PT2505204E (da)
RU (2) RU2504394C2 (da)
SI (3) SI2650012T1 (da)
TW (2) TWI442932B (da)
WO (2) WO2009101530A1 (da)
ZA (1) ZA201005697B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
JOP20090061B1 (ar) * 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
JO3525B1 (ar) * 2008-02-11 2020-07-05 Ferring Int Center Sa علاج سرطان البروستاتا في المرحلة النقيلية بدواء ديجاريليكس
BRPI1010874A8 (pt) * 2009-05-01 2018-01-02 Ferring Bv composição para o tratamento de câncer de próstata
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
FR2964323B1 (fr) * 2010-09-08 2012-11-09 Jean Pierre Raynaud Utilisation de la testosterone chez un patient en deficit androgenique et atteint d'un cancer de la prostate
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
WO2012055903A1 (en) 2010-10-27 2012-05-03 Ferring B.V. Process for the manufacture of degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
AU2012225232B2 (en) 2011-03-09 2016-05-12 Richard G. Pestell Prostate cancer cell lines, gene signatures and uses thereof
CN102204889B (zh) * 2011-05-23 2013-09-18 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法
WO2013104745A1 (en) * 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
CA2873743C (en) 2012-05-14 2022-12-06 Prostagene, Llc Using modulators of ccr5 for treating cancer
TWI580443B (zh) 2012-06-01 2017-05-01 菲瑞茵公司 地蓋瑞利（ｄｅｇａｒｅｌｉｘ）之製備技術
MY180834A (en) 2012-09-26 2020-12-10 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
US10881659B2 (en) 2013-03-15 2021-01-05 Abbvie Inc. Methods of treating heavy menstrual bleeding
US20140358576A1 (en) * 2013-05-15 2014-12-04 Adverse Events, Inc. System and method for surveillance and evaluation of safety risks associated with medical interventions
EP3185881B1 (en) * 2014-08-26 2022-03-09 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions
JP6941565B2 (ja) * 2015-05-12 2021-09-29 ドレクセル ユニバーシティ がん転移を処置または防止するのに有用な化合物および組成物、ならびにこれらの使用法
CN110248679A (zh) * 2017-01-30 2019-09-17 安迪威有限公司 包含至少一种GnRH拮抗剂的组合物
AU2018351714A1 (en) 2017-10-16 2020-04-30 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CA3097340A1 (en) 2018-04-19 2019-10-24 Abbvie Inc. Methods of treating heavy menstrual bleeding
CN112533603A (zh) * 2018-08-01 2021-03-19 艾伯维公司 噁拉戈利的给药方案
RU2731002C1 (ru) * 2019-10-22 2020-08-26 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения рака предстательной железы
CN116407494A (zh) * 2023-03-02 2023-07-11 山东大学齐鲁医院 一种醋酸地加瑞克注射液及其制备方法、用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4072668A (en) 1973-11-06 1978-02-07 The Salk Institute For Biological Studies LH-RH Analogs
EP0002749B2 (en) 1977-12-26 1987-08-12 IHARA CHEMICAL INDUSTRY Co., Ltd. Process for producing aromatic monocarboxylic acid
US5296468A (en) 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
DE69214818T2 (de) * 1991-04-25 1997-02-27 Romano Deghenghi LHRH-Antagonisten
EP0556034B2 (en) 1992-02-12 2004-07-21 Daikyo Gomu Seiko Ltd. A medical instrument
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
SI9300468A (en) 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US5506207A (en) 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5825730A (en) 1995-03-10 1998-10-20 Kabushiki Kaisha Toshiba Mastering machine having non-repetitive runout compensation
US6379669B1 (en) 1995-08-04 2002-04-30 Akhouri A. Sinha Targeting of organs by immunoconjugates
US5710246A (en) 1996-03-19 1998-01-20 Abbott Laboratories Process for intermediates for the synthesis of LHRH antagonists
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5925730A (en) 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
US5821230A (en) 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
US5977302A (en) 1997-11-20 1999-11-02 Ortho-Mcneil Pharmaceutical, Inc. Liquid phase process for the preparation of GnRH peptides
FR2776520B1 (fr) 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
CA2336879C (en) 1998-07-20 2010-06-01 Peptech Limited Sustained-release formulations comprising peptides, polypeptides, proteins or nucleic acids as active ingredients
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US20020103131A1 (en) 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
JP4619651B2 (ja) * 2001-06-01 2011-01-26 コーネル・リサーチ・ファンデーション・インコーポレイテッド 前立腺特異的膜抗原に対する修飾抗体およびその使用
GB0117057D0 (en) 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20070015713A1 (en) 2005-07-14 2007-01-18 Voyager Pharmaceutical Corporation Methods for treating prostate cancer
US20060234918A1 (en) * 2001-12-19 2006-10-19 Voyager Pharmaceutical Corporation Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
SE0104463D0 (sv) 2001-12-29 2001-12-29 Carlbiotech Ltd As Mellanprodukter för syntes af LHRH-antagonister, sätt att framställa dem och sätt för framställning av LHRH-antagonister
CN1411803A (zh) 2002-08-29 2003-04-23 四川大学 制备前体脂质体的方法及其装置
CA2507524C (en) 2002-09-27 2012-12-11 Zentaris Gmbh Administration form for pharmaceutically active peptides with sustained release and method for the production thereof
GB0223367D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
AR042815A1 (es) 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
EP1674082A1 (de) 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2006069779A1 (en) 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Preparing of peptides with excellent solubility
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007130809A2 (en) 2006-05-06 2007-11-15 Volodymyr Brodskyy An automatic injectable drug mixing device
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
IL182922A0 (en) 2007-05-02 2007-09-20 Medimop Medical Projects Ltd Automatic liquid drug reconstitution apparatus
US8283331B2 (en) 2007-10-09 2012-10-09 Children's Medical Center Corporation Methods to regulate miRNA processing by targeting Lin-28
SG2013054218A (en) 2008-01-15 2014-10-30 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
US8105292B2 (en) 2008-02-11 2012-01-31 Safety Syringes, Inc. Reconstitution means for safety device
PL2421887T3 (pl) 2009-04-24 2015-11-30 Polypeptide Laboratories As Sposób wytwarzania degarelix
BRPI1010874A8 (pt) 2009-05-01 2018-01-02 Ferring Bv composição para o tratamento de câncer de próstata
TW201043221A (en) 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
WO2011066386A1 (en) 2009-11-25 2011-06-03 Novetide, Ltd. Process for production of degarelix
ES2385240B1 (es) 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
WO2012055903A1 (en) 2010-10-27 2012-05-03 Ferring B.V. Process for the manufacture of degarelix and its intermediates
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
CN102204889B (zh) 2011-05-23 2013-09-18 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法
AU2012284200B2 (en) 2011-07-15 2016-09-22 Ferring B.V. Method for timing a colonoscopy wherein a picosulate composition is administered
TWI580443B (zh) 2012-06-01 2017-05-01 菲瑞茵公司 地蓋瑞利（ｄｅｇａｒｅｌｉｘ）之製備技術

Also Published As

Publication number Publication date
JP5876652B2 (ja) 2016-03-02
HK1198243A1 (en) 2015-03-20
KR20180118830A (ko) 2018-10-31
DK2505204T3 (da) 2015-03-16
EA200901074A1 (ru) 2010-04-30
US20170035833A1 (en) 2017-02-09
ES2479441T3 (es) 2014-07-24
US11766468B2 (en) 2023-09-26
CN103990107A (zh) 2014-08-20
KR20230088848A (ko) 2023-06-20
EA036695B1 (ru) 2020-12-09
WO2009101530A1 (en) 2009-08-20
JP2011511785A (ja) 2011-04-14
IL207400A0 (en) 2010-12-30
US9415085B2 (en) 2016-08-16
BRPI0908129A2 (pt) 2015-08-04
US8841081B2 (en) 2014-09-23
US10729739B2 (en) 2020-08-04
PT2249859E (pt) 2014-07-31
NZ587088A (en) 2012-12-21
AU2009213748B9 (en) 2014-05-22
EP2249859B1 (en) 2014-04-23
BRPI0908127A2 (pt) 2015-08-04
AU2009213748B2 (en) 2014-03-13
EP4257197A3 (en) 2023-11-29
IL223124A0 (en) 2012-12-31
RU2010133481A (ru) 2012-03-20
EP2505204A3 (en) 2013-01-09
HRP20150633T1 (hr) 2015-07-31
TWI539959B (zh) 2016-07-01
US20190167755A1 (en) 2019-06-06
JP6189234B2 (ja) 2017-08-30
US20090203623A1 (en) 2009-08-13
EA201300742A1 (ru) 2014-02-28
EA026521B1 (ru) 2017-04-28
CY1116341T1 (el) 2017-02-08
ZA201005697B (en) 2014-01-24
US20140349935A1 (en) 2014-11-27
CN101939020A (zh) 2011-01-05
JP2014141505A (ja) 2014-08-07
CA3235099A1 (en) 2009-08-20
PL2249859T3 (pl) 2014-10-31
IL207295A (en) 2015-03-31
EP2249859A1 (en) 2010-11-17
TW200938217A (en) 2009-09-16
EP2249858A1 (en) 2010-11-17
CA2714444A1 (en) 2009-08-20
US20090203622A1 (en) 2009-08-13
RU2504394C2 (ru) 2014-01-20
SI2650012T1 (sl) 2015-06-30
EA200901075A1 (ru) 2010-04-30
US10695398B2 (en) 2020-06-30
IL207295A0 (en) 2010-12-30
EP3360565A1 (en) 2018-08-15
EA017582B1 (ru) 2013-01-30
JP7400029B2 (ja) 2023-12-18
NZ587057A (en) 2012-12-21
US20220323538A1 (en) 2022-10-13
CY1115561T1 (el) 2017-01-04
EP2650012B1 (en) 2015-03-25
RU2010133480A (ru) 2012-03-20
US9877999B2 (en) 2018-01-30
TWI442932B (zh) 2014-07-01
AU2009213748A1 (en) 2009-08-20
EA201300741A1 (ru) 2014-02-28
HRP20140665T1 (hr) 2014-10-10
US11826397B2 (en) 2023-11-28
PL2505204T3 (pl) 2015-05-29
JP2011511786A (ja) 2011-04-14
KR20220009504A (ko) 2022-01-24
KR20150091543A (ko) 2015-08-11
US20220031801A1 (en) 2022-02-03
JP6618967B2 (ja) 2019-12-11
JP2022133426A (ja) 2022-09-13
SI2505204T1 (sl) 2015-04-30
JP2018039814A (ja) 2018-03-15
KR20100123714A (ko) 2010-11-24
KR101542480B1 (ko) 2015-08-07
ES2540235T3 (es) 2015-07-09
US10973870B2 (en) 2021-04-13
PT2505204E (pt) 2015-03-26
KR20140130757A (ko) 2014-11-11
DK2650012T3 (da) 2015-06-15
JP2022184898A (ja) 2022-12-13
CN101998861A (zh) 2011-03-30
US20220218783A1 (en) 2022-07-14
CN107412726A (zh) 2017-12-01
CN101939020B (zh) 2012-12-26
AU2009213751B2 (en) 2014-09-25
EP2505204A2 (en) 2012-10-03
HRP20150290T1 (hr) 2015-04-10
CY1116289T1 (el) 2017-02-08
JP5924866B2 (ja) 2016-05-25
EP2650012A1 (en) 2013-10-16
HK1176552A1 (en) 2013-08-02
KR20100126362A (ko) 2010-12-01
PT2650012E (pt) 2015-06-30
JP2014167009A (ja) 2014-09-11
JP2016216455A (ja) 2016-12-22
EP2799085A1 (en) 2014-11-05
PL2650012T3 (pl) 2015-08-31
NZ603932A (en) 2014-04-30
IL207400A (en) 2014-12-31
HK1145011A1 (en) 2011-03-25
EP2505204B1 (en) 2014-12-24
JP2016193910A (ja) 2016-11-17
CA2714445A1 (en) 2009-08-20
NZ603958A (en) 2013-03-28
EP4257197A2 (en) 2023-10-11
HK1190912A1 (en) 2014-07-18
CA2714445C (en) 2018-01-16
US9579359B2 (en) 2017-02-28
JP6254042B2 (ja) 2017-12-27
US20220218782A1 (en) 2022-07-14
US20140113870A1 (en) 2014-04-24
JP2024028869A (ja) 2024-03-05
EA020543B1 (ru) 2014-12-30
US20210128673A1 (en) 2021-05-06
US20170290879A1 (en) 2017-10-12
US20200237854A1 (en) 2020-07-30
US20220226422A1 (en) 2022-07-21
AU2009213751A1 (en) 2009-08-20
JOP20090061B1 (ar) 2021-08-17
RU2504393C2 (ru) 2014-01-20
ES2532709T3 (es) 2015-03-31
MX2010008817A (es) 2010-09-09
US20130029910A1 (en) 2013-01-31
TW200938218A (en) 2009-09-16
WO2009101533A1 (en) 2009-08-20
MX2010008816A (es) 2010-09-07
SI2249859T1 (sl) 2014-08-29

Similar Documents

Publication Publication Date Title
DK2249859T3 (da) Behandling af metastatisk prostatacancer med degarelix
BRPI0912683A2 (pt) tratamento de tumores metastáticos
DK2195015T3 (da) Sammensætning til behandling af prostatacancer
BR112012005594A2 (pt) tratamento de câncer
DK3289876T3 (da) Forbindelser til behandling af cancer
BR112012002797A2 (pt) tratamento de câncer de próstata
DK2278945T3 (da) Rektal drænindretning
BRPI0810206A2 (pt) Método de tratar câncer
BRPI1006075A2 (pt) biomarcadores de cancer
DK2127652T3 (da) Fremgangsmåde til behandling af cancer under anvendelse af anticancermiddel i kombination
BRPI1006438A2 (pt) terapia adjuvante de cancer
BRPI1013618A2 (pt) pirimidinas substituídas para o tratamento de câncer
DK2364166T3 (da) Undertrykkelse af cancer
BRPI1010874A8 (pt) composição para o tratamento de câncer de próstata
DK2318378T3 (da) Quinazolin-derivater
DK2101805T3 (da) Integrinligander til anvendelse i behandling af cancer
BRPI0916679A2 (pt) 5-alquinil-pirimidinas
DK2411009T3 (da) Terapeutiske anvendelser af quinazolindionderivater
BRPI0922884A2 (pt) compostos para tratamento de câncer
BR112012002083A2 (pt) inibição de metaste tumoral
DK2147122T3 (da) Enzymatisk kræftbehandling
DK2501381T3 (da) Behandling af atrieflimmer
BRPI0911977A2 (pt) quinazolinas substituídas
DK2254570T3 (da) Kombination omfattende paclitaxel til behandling af ovariecancer
DK2235021T3 (da) Epoxyguainderivater og behandling af cancer